MGI Tech Co. Ltd. announced partnerships with Genos Medica and TCL Group, a company dedicated to the import and sales of laboratory equipment and supplies in Chile, respectively. The two partnerships will see MGI providing its sequencing and lab automation platforms to local partners in Latin America, underscoring its commitment to expand genomics and transform human health in the region.

The healthcare landscape in Latin America has been changing swiftly, with demand for high-throughput sequencing technologies and testing growing as population ages, the number of cancer patients rises, and chronic diseases become more prevalent. Through genetic testing, scientific researchers are able to identify the sequence of DNA or RNA to study genetic variation associated with diseases and respond with tailored treatment. However, limited access to relevant technologies and training programs due to high instrument and maintenance costs has notably hindered the development of the space and widespread adoption of high-throughput sequencing.

In this regard, MGI is determined to facilitate genomics for all by empowering local laboratories and institutes with innovative life science tools and enhancing their genetic testing capabilities. Meanwhile in Chile, TCL Group, a renowned company with 28 years of experience providing diagnostics and biotech solutions locally, has joined hands with MGI to import five units of the versatile DNBSEQ-G400 benchtop sequencing and three of the ultra-high speed DNBSEQ-G99 sequencer, providing their customers with accurate, efficient and cost-effective sequencing options. Additionally, TCL Group has also purchased MGISP-960 and MGISP-100 automated sample preparation systems to accommodate emerging market needs.

With LATAM as one of its focus markets, MGI has consistently demonstrated its commitment to expediting the adoption of cutting-edge sequencing technologies and advancing patient care within the region. Earlier this year, MGI announced partnerships with Gencell in Colombia to realize this goal. Integrating Gencell's expertise and local market presence with MGI's advanced DNBSEQ??

technology, the collaboration aims to enhance Gencell's sequencing capacity and data analysis capabilities with a complete workflow that includes some of MGI's extensive products, such as DNBSEQ-T7, DNBSEQ-G 400, MGISP-100, MGISP-100 and ZTRON. Lastly, to increase the level of support for customers and partners in Latin America, MGI is set to open a new Customer Experience Center (CEC) in Sao Paulo, Brazil by First Quarter 2024. As a service hub, the future CEC will provide the growing number of local MGI customers and partners with expertise in high-throughput sequencing technology and specialized automation workflows to further upgrade local technical expertise across Latin America.

Looking ahead, MGI will continue to work closely with customers and partners in Latin America to lower barriers to genomics access, empower scientific breakthroughs and improve human health through its highly advanced and accessible life sciences technologies.